CCM
PCRX icon

CAAS Capital Management’s Pacira BioSciences PCRX Stock Holding History

CAAS Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,000
Closed -$502K – 857
2022
Q4 		$502K Buy
+13,000
New +$632K 0.03% 447

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

CAAS Capital Management's PCRX Position: Q1 2023 in Review

CAAS Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 13,000 shares — an estimated $502K sold.

CAAS Capital Management first reported a position in PCRX in Q4 2022 and held it in 1 quarter. The position peaked at $502K in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • CAAS Capital Management reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 13,000 Pacira BioSciences shares in Q1 2023, an estimated $502K.
  • CAAS Capital Management first reported a position in Pacira BioSciences in Q4 2022 and held it in 1 quarter.
  • CAAS Capital Management's Pacira BioSciences position peaked at $502K in Q4 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.